invest to develop a more professional structure

enhance management, administration, coordination & communications

build a more efficient, integrated organisation & team approach

increase precision in stratification, treatment & disease monitoring

improve molecular characterisation & extend biomarker research

pursue targeted agents, immunotherapies & combination therapies

renew focus on education, training & mentorship

increase involvement of early-career researchers

retain talent & develop new leadership potential

streamline & standardise operational elements

build capability to deliver & open trials more quickly & efficiently

develop & deliver studies for high-risk, non-high-risk & relapse patients

enhance collaboration with other research networks including ITCC & COG

build engagement strategies for regulatory agencies & pharma companies

increase engagement & involvement of advocates

implement fit-for-purpose infrastructure to efficiently collect & store data

build core data dictionary & standardise terminology across trials

increase involvement of statisticians + collaboration with other groups